Alzheimer's disease dementia
Conditions
Interventions
None listed
Sponsors
Centre for Human Drug Research
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Males and females, aged 60 and older (inclusive); 2. Willing and able to perform the cognitive tests, as evidenced by performance on the training session of the cognitive tests. 3. Willing and able to give written informed consent and to comply with the study procedures.
Exclusion criteria
Exclusion criteria: 1. Legal incapacity or inability to understand or comply with the requirements of the study; 2. Evidence of severe cognitive deterioration, as indicated by a diagnosis of severe cognitive disorder (including but not limited to Alzheimer*s disease, Lewy Body Dementia, Fronto-temporal Dementia); 3. History or symptoms of significant psychiatric disease (including but not limited to clinical depression, schizophrenia); 4. A Mini Mental State Examination (MMSE) score of
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NeuroCart assessments * Adaptive tracking test; * Visual Verbal Learning Test (VVLT); * Milner Maze test; * Visual Analogue Scales according to Bond and Lader (VAS-BL); alertness, mood and calmness; * Face encoding and recognition test; * N-back test; * Sustained Attention to Response test (SART); * 21 leads electroencephalogram (EEG) * Event related potentials (ERPs; P50, P300, N100 and mismatch negativity [MMN]); Neuropsychological tests * Animal fluency test; * Clinical Dementia Rating scale (CDR); * Alzheimer*s Disease Assessment Scale * Cognition (ADAS-Cog); * Amsterdam Instrumental Activities of Daily Living scale (Amsterdam iADL); * Pittsburgh Sleep Quality Index (PSQI). Biochemical outcome variables CSF biomarkers * A* concentration (1-40, 1-42) * Total tau concentration (Tau-t) * Phosphorylated tau concentration (Tau-p) * Exploratory markers (e.g. Neurogranin, VILIP-1) Exploratory plasma biomarkers * A* concentration (1-40, 1-42) * Tau-t and Tau-p concentrations * Acute phase & inflammatory proteins Genetics * APOE genotype | — |
Countries
Netherlands
Outcome results
None listed